Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas

Next Previous
X
Search
Trial Profile

A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Prednisone; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 14 Dec 2020 Status changed from active, no longer recruiting to completed.
    • 23 Aug 2019 Planned End Date changed from 1 Nov 2018 to 1 Aug 2023.
    • 04 Dec 2018 Preliminary results assessing evaluating clinicopathologic diagnosis compared to gene expression in B cell lymhoma patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top